About Curodont™
The first product of credentis that will be submitted for market approval (CE-label) will be Curodont™ with the self-assembling peptide P11-4.
Curodont™ provides dentists with a novel technology to regenerate rather than repair carious and other tooth lesions. Applied to a small lesion, Curodont™ forms a scaffold of small fibres within the lesion around which new enamel or dentin can form and grow. Ideally, within several weeks the lesion will regenerate without the use of burr or filler.
The presented results from the clinical study at Leeds are very encouraging: “We want to develop not only a product, but a new approach to caries. This will revolutionize dental care”, explains Dominik Lysek. The ultimate goal is to prevent caries by frequent recalls to dentists and dental hygienists.
Within additional clinical studies credentis continues to optimize and test the application and the range of indications of Curodont™.
About credentis ag
credentis has its headquarters in the Technopark Aargau Switzerland, Windisch; it has already won the support of Genilem and presented itself successfully at various events including the Argovian and Swiss Equity Fairs and was one of Swiss Venture Leaders 2011.
CEO Dominik Lysek and CTO Michael Hug have expert knowledge in medicinal technology and a strong network in the dental industry. Dr. Werner Berner (member of the board) and Dr. Erich Platzer (chairman of the board) perfectly complement the know-how of the management and contribute to the success of the young company with their expert industry knowledge.
Contact: Dr. Dominik Lysek, CEO, tel +41 56 560 2044; info@credentis.com
